Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | 300433 | PO / MO |
The patient took the Vivotif and between the second and third dose there was a three-day interval, and between the 2nd and fourth dose there was a five-day interval.; Case reference number US-BN-2025-001580 is a spontaneous case initially received from a nurse via Communication (reference number: USBAV25-2345) on 22-Sep-2025 and concerns a 22-year-old male patient. The patient's medical history included history of anxiety and obstructive sleep apnea. The patient's concomitant medication details were not provided. On 17-Sep-2025, the patient took the first dose of Vivotif (batch number: 300433 and *expiration date 31-Jul-2026*), orally, *1 capsule*, for pre travel vaccination for travel. On 19-Sep-2025, two days from the first dose, the patient took the second dose of Vivotif (batch number: 300433 and *expiration date 31-Jul-2026*), orally, *1 capsule*. *On 22-Sep-2025, three days from the second dose, the patient took the third dose of Vivotif (batch number: 3004333 and expiration date 31-Jul-2026), orally, 1 capsule, for indication of typhoid immunization (explicitly coded as 'inappropriate schedule of vaccine administered'). * *On 24-Sep-2025, five days from the second dose, the patient took the fourth dose of Vivotif (batch number: 3004333 and expiration date 31-Jul-2026), orally, 1 capsule (explicitly coded as 'inappropriate schedule of vaccine administered'). * At the time of the *follow-up* report, it was *reported that the patient did not experience* any adverse event due to Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from a health care professional on 21-Oct-2025: New information included additional patient details, suspect product details, and adverse events details.; Reporter's Comments: This case concerns a 22-year-old male patient, who had received the third dose of Vivotif vaccine, 3 days after the second dose and fourth dose, 5 days after the second dose, for an indication of pre travel vaccination, which is considered as inappropriate schedule of product administration. At the time of the follow-up report, it was reported that the patient did not experience any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed as per company convention. The patient's medical history included history of anxiety and obstructive sleep apnea, and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 22-year-old male patient, who had received the third dose of Vivotif vaccine, 3 days after the second dose and fourth dose, 5 days after the second dose, for an indication of pre travel vaccination, which is considered as inappropriate schedule of product administration. At the time of the follow-up report, it was reported that the patient did not experience any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed as per company convention. The patient's medical history included history of anxiety and obstructive sleep apnea, and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Medical History/Concurrent Conditions: Anxiety; Obstructive sleep apnea